Li Yue-Yang, Hu Dong-Zhi, Wang Ya-Fei, Zhao Zhi-Gang, Cao Zeng, Zhang Yi-Zhuo, Zhang Hui-Lai, Tian Chen
Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Jun;28(3):849-854. doi: 10.19746/j.cnki.issn.1009-2137.2020.03.021.
To analyze the clinical and pathological characteristics of primary gastrointestinal non-Hodgkin's lymphoma (PGI-NHL) patients, and to explore the factors affecting the patients' survival and prognosis.
The clinical data of 219 patients with PGI-NHL diagnosed in our hospital from March 2009 to April 2016 was collected and retrospectively analyzed. Survival analysis was performed by using the Kaplan-Meier method. Log-rank test was used for comparison among the groups, and Cox regression was used for multivariate analysis.
Among the 219 patients with PGI-NHL, 126 patients were males and 93 patients were females. 182 patients were IPI 0 to 2 and 37 patients were IPI 3 to 5. There were 205 cases (93.6%) of B cell phenotype and 14 cases (6.4%) of T cell phenotype. 140 patients (63.9%) were patients with primary gastric NHL, including 85 DLBCL and 19 MALT. 79 cases (36.1%) were patients with primary intestinal NHL, including 46 DLBCL, 4 MALT, 7 FL, 3 MCL and 4 Burkitt lymphoma. 23 cases were HP positive and received anti-HP therapy. 57 cases and 32 cases received surgery and chemotherapy respectively. 84 cases received combination treatment of surgery and chemotherapy and 11 cases received combination treatment of radiotherapy and chemotherapy. Overall survival (OS) of indolent B-cell non-Hodgkin's lymphoma was longer than that of invasive B-cell non-Hodgkin's lymphoma, which shows better prognose. Kaplan-Meier analysis showed that there was no difference between progression-free survival (PFS) and OS in the patients with different origin sites, age and sex. There was no significant difference in PFS between B-cell and T-cell-derived patients, whereas OS of B-cell-derived PGI-NHL patients was longer than that of T-cell-derived PGI-NHL patients. The OS and PFS of patients with IPI 0-2 were longer than those of patients with IPI 3-5. According to Lugano and Ann Arbor staging systems, there was no difference in prognosis of patients between phase I/II and III/IV. The prognosis of patients treated with surgery alone was worse than that of patients treated with combination therapy, and the prognosis of patients with surgery combined with chemotherapy was not significantly different from that of patients with chemotherapy alone.
B-cell phenotype, indolent and low IPI score lymphoma indicate better prognosis, while that of different origin site, sex and age shows no different in prognosis. Surgery is used only for emergency case or pathological materials, and these patients should be treated with chemotherapy-based combined treatment.
分析原发性胃肠道非霍奇金淋巴瘤(PGI-NHL)患者的临床及病理特征,探讨影响患者生存及预后的因素。
收集我院2009年3月至2016年4月诊断的219例PGI-NHL患者的临床资料并进行回顾性分析。采用Kaplan-Meier法进行生存分析。组间比较采用Log-rank检验,多因素分析采用Cox回归。
219例PGI-NHL患者中,男性126例,女性93例。国际预后指数(IPI)0至2分者182例,3至5分者37例。B细胞表型205例(93.6%),T细胞表型14例(6.4%)。原发性胃NHL患者140例(63.9%),其中弥漫大B细胞淋巴瘤(DLBCL)85例,黏膜相关淋巴组织淋巴瘤(MALT)19例。原发性肠道NHL患者79例(36.1%),其中DLBCL 46例,MALT 4例,滤泡性淋巴瘤(FL)7例,套细胞淋巴瘤(MCL)3例,伯基特淋巴瘤4例。23例幽门螺杆菌(HP)阳性并接受抗HP治疗。57例和32例分别接受手术和化疗。84例接受手术联合化疗,11例接受放疗联合化疗。惰性B细胞非霍奇金淋巴瘤的总生存期(OS)长于侵袭性B细胞非霍奇金淋巴瘤,预后较好。Kaplan-Meier分析显示,不同原发部位患者的无进展生存期(PFS)和OS无差异,年龄和性别对PFS和OS也无显著影响。B细胞来源和T细胞来源患者的PFS无显著差异,但B细胞来源的PGI-NHL患者的OS长于T细胞来源者。IPI 0 - 2分患者的OS和PFS长于IPI 3 - 5分者。根据卢加诺和安阿伯分期系统,Ⅰ/Ⅱ期和Ⅲ/Ⅳ期患者的预后无差异。单纯手术治疗患者的预后较联合治疗者差,手术联合化疗患者的预后与单纯化疗者无显著差异。
B细胞表型、惰性及低IPI评分的淋巴瘤预后较好,而不同原发部位、性别及年龄患者的预后无差异。手术仅用于紧急情况或获取病理材料,此类患者应以化疗为主进行联合治疗。